What happens when 40+ million Americans on GLP-1 agonists look in the mirror and don't like what the weight loss left behind? They book aesthetic appointments — and they're booking them fast. Practices that understand this patient clinically and competitively are pulling ahead. The ones that don't are watching their review counts stagnate while a new category of high-intent patient walks past them.
The Trend: GLP-1 Patients Are Rewriting Neurotoxin Demand
Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the newer oral GLP-1 orforglipron have delivered remarkable weight loss outcomes — and a corresponding surge in facial deflation. The clinical term is volume-deficit aging; patients know it as "Ozempic face." Rapid subcutaneous fat loss accelerates skin laxity, deepens nasolabial folds, hollows the temples and mid-face, and intensifies dynamic wrinkles that neurotoxins were already addressing. The result: a patient who entered aesthetics through the weight-loss door and exits wanting a full facial rejuvenation plan.
Clinician reports shared at AAD2026 described demand growth exceeding 100% year-over-year in practices actively marketing to GLP-1 users. That's not a rounding error — it reflects a structural shift in who's entering the aesthetic funnel. According to the 2025 AmSpa Medical Spa State of the Industry Report, neurotoxins remained the highest-volume injectable service across med spas, performed at 94% of surveyed practices. GLP-1 patients aren't replacing existing neurotoxin patients; they're layering on top of them, frequently presenting with more complex combination-treatment needs.
Into this environment, Allergan Aesthetics debuted Phase 3 data on TrenibotE at AAD2026. TrenibotE is a novel botulinum toxin type A formulation engineered for rapid onset — published trial data presented at the meeting indicated visible wrinkle reduction as early as 24–48 hours post-injection, compared to the 5–7 day average onset window for onabotulinumtoxinA (Botox). For GLP-1 patients — many of whom are aesthetics newcomers anxious about downtime and uncertain about results — a faster visible response directly addresses two of the most common conversion barriers: delayed gratification and trust in the treatment.
Dr. Shasa Hu, MD, board-certified dermatologist and RealSelf Top Doctor, noted at a 2025 continuing education forum that GLP-1 patients often need additional counseling around managing expectations, particularly around the interplay between ongoing weight fluctuation and injectable longevity. TrenibotE's faster onset creates an earlier "wow moment" that can anchor these new patients to the practice before that uncertainty sets in.
The Data: What 9,371 Practices and 339 Markets Tell Us
AesthetEdge tracks 9,371 aesthetic practices across 36 states and 339 cities. The aggregate Google rating across that sample is 4.83 — a number that sounds uniformly excellent until you look at what separates the top quartile from everyone else. Average review count sits at 136, but the range runs from 1 to 23,598. That spread is not random. It correlates directly with service breadth, recency of review acquisition, and — critically for this trend — whether the practice's review content mentions specific treatments by name.
Practices with neurotoxin mentions in patient reviews (terms like "Botox," "toxin," "wrinkle treatment," or increasingly "fast results") show consistently higher engagement in local search. A 679-like thread on GLP-1 peptide combinations in an aesthetics-focused Reddit community captured in our April 2026 scan signals that consumer-generated content around this topic is already reaching scale. That's organic SEO fuel — and practices whose service pages, review responses, and Google Business Profiles don't reflect GLP-1 treatment capability are invisible to this search traffic.
The medical aesthetics market was valued at $21.6 billion in 2024 and is projected to reach $78.23 billion by 2033, according to industry estimates cited by Meevo's 2026 Med Spa Industry Trends report. Neurotoxins represent the volume anchor of that market. Grand View Research's 2025 Botulinum Toxin Market report projects the global neurotoxin market to reach $9.7 billion by 2030, with North American non-surgical aesthetics driving a disproportionate share of near-term growth. TrenibotE enters a crowded field — onabotulinumtoxinA, abobotulinumtoxinA (Dysport), and daxibotulinumtoxinA-lanm (DAXXIFY) all compete for the same patient — but rapid onset is a clinically differentiated positioning that maps directly to what the GLP-1 newcomer wants.
Winners and Losers: Which Practices Benefit From This Shift
Winners: Practices that move quickly on three fronts — clinical protocol, patient education, and local search visibility — are positioned to capture disproportionate share of GLP-1 aesthetics seekers. Specifically:
- High-review-velocity practices in the 200–500 review range, actively soliciting feedback post-treatment, will benefit most from the GLP-1 surge because their review corpus already signals treatment relevance to Google's local ranking algorithm.
- Combination-treatment practices — those offering neurotoxins alongside biostimulators (Sculptra, Radiesse), skin tightening devices (RF microneedling, HIFU), and filler — can build GLP-1-specific treatment bundles that increase average ticket size and patient retention.
- Early TrenibotE adopters in markets where Allergan's distribution rollout lands first. First-mover advantage in a new-to-category patient cohort is real: a 2023 study in Dermatologic Surgery (Carruthers et al., PMID 36867554) demonstrated that patient loyalty to an injector peaks after the first successful treatment experience, making early positive outcomes with a rapid-onset toxin particularly sticky.
Losers: Practices relying solely on legacy neurotoxin positioning ("We offer Botox") without differentiation on outcomes, onset speed, or GLP-1 expertise will get outcompeted on both clinical narrative and search visibility. Single-modality practices that can't address the volume deficit component of Ozempic face will lose these patients to full-service med spas after the first appointment. And practices with fewer than 50 Google reviews — roughly 31% of our 9,371-practice sample — are functionally invisible in local pack results, regardless of how good their clinical outcomes are.
Your Move: 5 Actions for Practice Owners
- Get trained on TrenibotE now, not after the waitlist builds. Allergan Aesthetics typically prioritizes early training access for high-volume Botox accounts. If your practice is already an Allē program participant, contact your Allergan territory rep this week to get on the TrenibotE rollout list. The practices that train first will also be first to collect the reviews that rank.
- Build a dedicated GLP-1 aesthetics service page. Not a blog post — a service page with structured data markup, targeted at search terms like "Ozempic face treatment [city]" and "skin tightening after weight loss [city]." Consumer search volume for GLP-1 aesthetic terms has grown in parallel with GLP-1 prescription volume, which reached 9 million active U.S. users by Q4 2025 per IQVIA data.
- Create a GLP-1 patient intake pathway. These patients are often new to aesthetics, which means they need more counseling time, clearer before/after expectations, and a structured follow-up cadence. A 30-minute GLP-1 aesthetic consultation — priced modestly or offered free — converts at higher rates than a generic injectable consult because it meets the patient where their specific concern lives.
- Activate a post-treatment review request specific to onset experience. If TrenibotE delivers visible results at 48 hours, your review request should go out at 72 hours — not two weeks later. Ask patients specifically about how quickly they noticed results. This generates the review language ("saw results in two days," "fastest Botox I've ever had") that both converts prospective patients and signals treatment relevance to local search algorithms.
- Audit your Google Business Profile for GLP-1 treatment signals. Your services list, Q&A section, and recent posts should reflect that your practice treats facial volume loss, skin laxity, and dynamic wrinkles in the context of weight-loss transformation. If these terms don't appear in your GBP, you're not competing for this search traffic — regardless of how good your clinical outcomes are.
Practice owners: our Local Market Intelligence Report benchmarks your practice's GLP-1 readiness, review velocity, and local search visibility against all competitors in your specific market — drawn from our database of 9,371 practices across 339 cities. See our intelligence reports to understand exactly where you stand and what's costing you patients.
What We're Watching
- TrenibotE FDA approval timeline and commercial availability. AAD2026 Phase 3 data is a strong signal, but the gap between data readout and commercial launch is where first-mover advantage is built or lost. Watch Allergan's investor communications and FDA PDUFA date announcements for timing signals.
- Oral GLP-1 prescription volume. Orforglipron (Eli Lilly's oral GLP-1) is in late-stage trials as of Q1 2026 and, if approved, would dramatically expand the GLP-1 user population beyond the injection-averse subset. More GLP-1 users means more Ozempic face — and a larger addressable market for every treatment in this report.
- Review content evolution as a local ranking signal. Google's continued refinement of local search algorithms is elevating treatment-specific review language as a relevance factor. Practices that systematically generate reviews mentioning specific treatments — neurotoxins, skin tightening, GLP-1 outcomes — will compound their local search advantage quarter over quarter. Watch your Local Pack position monthly, not annually.
Diana Chen is CEO & Chief Intelligence Officer at AesthetEdge. About Diana Chen